Search

Search Constraints

You searched for: Author/Creator Paredes, V.

Search Results

2. Short course of R‐HyperCVAD/MTX/ARA‐C followed by ASCT as first‐line therapy in mantle cell lymphoma patients prolongs progression‐free survival to more than 9 years. (June 2017)